Recent studies have overturned the traditional belief that the lower respiratory tract is sterile. Instead, the lung environment hosts a dynamic lung microbiome whose composition in healthy individuals differs from that observed in respiratory disease. The review synthesizes current evidence showing distinct microbial communities between health and disease states and emphasizes that these differences are shaped by host factors and external exposures.
Microbial populations in the lung are not static; they fluctuate in response to local environmental conditions, immune status, and external influences. The authors describe how characterizing these baseline differences is essential for interpreting disease-associated changes and for distinguishing normal microbial dynamics from pathological dysbiosis.
The review details variations in microbial composition across multiple respiratory diseases. It discusses how the lung microbiome differs among patients with chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, lung cancer, COVID-19, and tuberculosis compared with healthy controls. Rather than a single disease-specific signature, the authors note heterogeneous alterations that reflect disease mechanisms, treatment exposures, and host responses.
Examples of disease-associated patterns include shifts in dominant taxa, loss of microbial diversity, and enrichment of potentially pathogenic species in certain conditions. The review highlights that these patterns vary by disease and likely contribute differently to clinical manifestations and outcomes.
The lung microbiome contributes to respiratory homeostasis through interactions with the mucosal immune system and by occupying ecological niches that might otherwise be taken by pathogens. The review frames the microbiome as an active participant in lung health, influencing local immune tone and barrier functions.
In health, balanced microbial communities appear to support normal immune surveillance and tolerance. Disruption of this balance may alter inflammatory responses and predispose to infection or chronic inflammation. The authors underscore the importance of defining what constitutes a healthy lung microbiome to guide clinical interpretation.
Microbial differences described in the review correlate with measures of disease severity and progression in various respiratory illnesses. Alterations in microbial composition and diversity are discussed as potential markers of worsening disease or predictors of clinical trajectory.
While the review highlights associations between microbiome features and disease states, it also notes complexity: microbial changes may be both cause and consequence of disease processes, influenced by treatments such as antibiotics, inhaled therapies, and host comorbidities. The authors advocate for longitudinal studies to clarify temporal relationships between microbiome shifts and clinical outcomes.
The review examines mechanisms through which the lung microbiome can contribute to disease pathogenesis. These include modulation of host immune responses, promotion of local inflammation, direct pathogenic effects of certain microbial species, and interactions with the pulmonary microenvironment that favor persistence or virulence.
Mechanistic insights discussed emphasize host-microbe crosstalk, immune dysregulation, and microbial metabolic activity as contributors to disease initiation and exacerbation. The authors outline how understanding these mechanisms could reveal targets for intervention.
Beyond local effects, the review explores systemic implications of lung microbiome alterations. It highlights emerging concepts of the gut-lung axis and brain-lung axis, which reflect bidirectional interactions between pulmonary microbial communities and distant organ systems.
The gut-lung axis concept posits that gut microbiota can influence lung immunity and susceptibility to respiratory disease through immune modulation and metabolic mediators. The brain-lung axis refers to potential neural and humoral pathways linking central nervous system function with pulmonary immune responses and microbial dynamics. The review presents these axes as important frameworks for understanding multisystem impacts of microbiome perturbations.
The authors conclude that characterizing lung microbial dynamics has practical implications. Microbiome profiles may inform novel diagnostics, risk stratification, and personalized therapeutic approaches for respiratory diseases. Potential strategies include targeted modulation of microbial communities, biomarker development, and interventions aimed at restoring microbial balance.
The review positions microbial dynamics as a promising avenue for translational research but underscores that further work is needed to translate observational findings into validated clinical tools. Specifically, the authors call for standardized sampling, longitudinal cohorts, and mechanistic studies to move from association to causation and to design safe, effective interventions.
Note: The source is a narrative review; specific study data, numerical outcomes, and detailed experimental results were not reported in the abstract and therefore are not detailed here.